FDA must go easy on OTC drug makers—but who pays if safety slips?
H.R. 6868 — ACCESS Through OTC Innovation Act · Filed by Greg Landsman (D-OH) · Introduced Dec 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill amends FDA rules for over-the-counter (OTC) drugs to require the agency to use the 'least burdensome' approach when evaluating whether a drug is safe and effective, and to hold meetings with drug makers to advise them on what evidence they need to submit. The FDA must document these meetings and recommendations in writing. The primary beneficiaries are OTC drug manufacturers, who gain clearer guidance and a lighter regulatory touch; consumers may benefit from faster access to OTC drugs, but the bill does not explicitly strengthen safety oversight.
Why we flagged it
The bill's core function is to reduce regulatory burden on OTC drug manufacturers by mandating a 'least burdensome' standard and FDA-industry meetings. This is a deregulatory measure framed as consumer access, but the primary mechanism benefits industry compliance costs.
What the text implies
- The 'least burdensome' standard may create a regulatory floor below which the FDA cannot demand evidence, potentially allowing drugs with weaker safety data to reach consumers.
- Mandatory pre-submission meetings and written guidance could accelerate approval timelines but may also lock in industry expectations, making it harder for FDA to later tighten standards without appearing to breach its own guidance.
- The bill does not define 'generally recognized as safe and effective' or clarify how 'least burdensome' interacts with existing GRAS/E standards, creating potential litigation risk and regulatory uncertainty.
Who it affects
Citizens may gain faster access to OTC drugs and clearer regulatory pathways, but the 'least burdensome' standard could lower the evidentiary bar for safety and efficacy, potentially allowing less-tested products to market. The bill does not restrict FDA's ultimate authority to deny approval, but it shifts the burden toward lighter scrutiny.
Who stands to gain
- OTC drug manufacturers
- pharmaceutical companies with OTC portfolios
- contract research organizations (CROs) advising on study design
Named in the bill
FDA, Federal Food, Drug, and Cosmetic Act, Section 505G, Section 201, OTC drug manufacturers
Where it stands
- Dec 18, 2025 — Introduced · Congress.gov: “Introduced in House”
- Dec 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
2 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $915,234 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 41% of bills with at least one filing.
Greg Landsman, the sponsor, reported $1,006,728 in PAC receipts in the 2026 cycle.
- Haleon Us Holdings LLC — $470,000 on 2 filings
- Consumer Healthcare Products Association — $445,234 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 2, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA must go easy on OTC drug makers—but who pays if safety slips?” QuorumCivic. https://share.quorumcivic.app/bill/119/hr6868 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.